Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
申请人:Novo Nordisk A/S
公开号:US10717784B2
公开(公告)日:2020-07-21
The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPIα, even where the concentration of TFPI is abnormally elevated.
该申请公开了两种单特异性 TFPI 抗体(其中一种抗体能特异性结合 TFPI(1-181),另一种抗体能特异性结合 TFPI(182-276)))的组合,以及由两种此类单特异性抗体衍生的双特异性抗 TFPI 抗体。即使在 TFPI 浓度异常升高的情况下,两种单特异性抗体和双特异性抗体的组合也能通过中和全长 TFPIα 而强烈促进凝血酶的生成。